Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose

NCT00338026 is registered in ClinicalTrials.gov with Thallion Pharmaceuticals as lead sponsor.

NCT NCT00338026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose
Lead sponsor
Thallion Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2006
Completion date
August 31, 2007
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, glioma, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, tumors